Emmaus Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

CONVERTIBLE DEBT AND EQUITY FINANCINGS (Tables)

CONVERTIBLE DEBT AND EQUITY FINANCINGS (Tables)

12 Months Ended

Sep. 30, 2017

The below table sets forth details regarding the shares issued to certain related parties upon the Company’s exercise of the Mandatory Conversion:

Note Issuance and Conversion Table:

Note Holder		Principal Amount		2016 Discount		Carrying Value September 30, 2016		Accrued Interest at Conversion		Shares issued on Conversion
Original Note Purchase Agreement
Note Date Range Sept 22, 2014 to July 20, 2015
RSJ Private Equity	(1)	$	750,000	$	21,300	$	728,700	$	76,200		165,246
John Pappajohn	(2)		200,000		8,100		191,900		20,400		44,089
John Pappajohn	(5)		200,000		3,000		197,000		14,200		42,820
Tierney Family Trust	(3)		540,000		16,000		524,000		46,000		117,199
Follman Family Trust	(4)		100,000		3,000		97,000		7,700		21,538
Oman Ventures	(6)		200,000		8,100		191,900		20,400		44,089
4 Accredited Investors			300,000		9,100		290,900		30,600		66,112
Subtotal for First Round		$	2,290,000	$	68,600	$	2,221,400
Omnibus Amendment Sept 14, 2015
Note Date Range Sept 14, 2015 to September 24, 2015
RSJ Private Equity	(1)	$	350,000	$	85,400	$	264,600		17,300		73,462
Robin Smith	(2)		60,000		7,100		52,900		3,100		12,611
John Pappajohn	(2)		100,000		24,400		75,600		5,100		21,015
Follman Family Trust	(4)		150,000		36,500		113,500		7,600		31,522
2 Accredited Investors			50,000		12,200		37,800		2,500		10,508
Subtotal for Second Round		$	710,000	$	165,600	$	544,400
Balances at September 30, 2015		$	3,000,000	$	234,200	$	2,765,800
Second Amended Note December 23 & 28, 2015
RSJ Private Equity	(1)	$	750,000						27,300		155,465
John Pappajohn	(2)		250,000						9,300		51,856
Subtotal for Third Round		$	1,000,000
Note Date Range Feb 23, 2016 to August 16, 2016
RSJ Private Equity	(1)	$	250,000						1,400		50,281
Robin Smith	(2)		40,000						800		8,165
John Pappajohn	(2)		850,000						14,000		172,802
Tierney Family Trust	(3)		100,000						600		20,129
Follman Family Trust	(4)		300,000						5,100		61,014
Carpenter, George & Jill	(7)		100,000						1,300		20,254
Harris, Geoffrey	(2)		10,000						300		2,058
2 Accredited Investors			300,000						5,600		61,124
Brandt Ventures	(8)		50,000						200		10,047
Subtotal for Final Round		$	2,000,000
Balances Converted September 19, 2016		$	6,000,000					$	317,000		1,263,406

(1)

RSJ PE is a greater than 5% shareholder. Michal Votruba, a Director for Life Sciences for the RSJ/Gradus Fund, subsequently joined our Board on July 30, 2015.

(2)

Member of the Board.

(3)

Thomas Tierney is a trustee of the Tierney Family Trust. Mr. Tierney originally joined the Board in February 25, 2013 and served as Chairman of the Board from March 26, 2013 till May 22, 2015 when he resigned from the Board. On September 29, 2016 Mr. Tierney rejoined the Board. The Tierney Family Trust is a greater than 5% shareholder of the Company. Mr. Tierney resigned from the board on July 14, 2017.

(4)

Robert Follman is a trustee of the Follman Family Trust and is a member of the Board. Mr. Follman resigned from the board on July 14, 2017.

(5)

John Pappajohn is a member of the Board. He purchased $200,000 of Notes, which on September 6, 2015, were assigned to four accredited investors. Approximately $10,400 of interest was attributable to such transferred Notes, resulting in an aggregate of 42,084 shares being issued upon the Mandatory Conversion of such transferred Notes.

(6)

Mark & Jill Oman are the beneficial owners of Oman Ventures and were greater than 5% shareholders of the Company.

(7)

George Carpenter is the CEO of the Company.

(8)

Brandt Ventures was issued this note as part of the Company’s settlement of its litigation with Leonard Brandt and Brandt Ventures (refer to Note 9. Commitments and Contingent Liabilities).